UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000028668 |
|---|---|
| Receipt number | R000032801 |
| Scientific Title | Canagliflozin heart failure with preserved ejection fraction study in type 2 diabetes mellitus |
| Date of disclosure of the study information | 2017/10/01 |
| Last modified on | 2021/08/19 18:19:09 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Canagliflozin heart failure with preserved ejection fraction study in type 2 diabetes mellitus
Acronym
CANONICAL Study
Scientific Title
Canagliflozin heart failure with preserved ejection fraction study in type 2 diabetes mellitus
Scientific Title:Acronym
CANONICAL Study
Region
| Japan |
Condition
Condition
Heart failure with preserved ejection fraction in type 2 diabetes mellitus
Classification by specialty
| Cardiology | Endocrinology and Metabolism |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
The aim of this study is to compare the effects of canagliflozin 100mg administered once a day for 24 weeks on cardiac function using body weight and BNP as indicators in elderly patients with type 2 diabetes mellitus harboring HFpEF with canagliflozin.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Explanatory
Developmental phase
Not applicable
Assessment
Primary outcomes
1) The change in BNP at week 24 from the baseline.
2) The change in body weight at week 24 from the baseline.
Key secondary outcomes
1) Hospitalization for heart failure
2) Cardiovascular death / total death
3) The change of body weight at each measurement point from the baseline.
4) The change of dose under loop diuretics.
5) The change in HbA1c from the baseline.
6) The change in BNP and NT-proBNP at each measurement point from the baseline.
7) Echocardiography
8) CONUT score and GNRI
9) FT3, FT4, TSH
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Open -no one is blinded
Control
Active
Stratification
YES
Dynamic allocation
YES
Institution consideration
Institution is not considered as adjustment factor.
Blocking
NO
Concealment
Central registration
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Interventions (The group with Canagliflozin)
The period of intervention: 0-24 weeks.
The dosage of Canagliflozin: 100mg/day.
Interventions/Control_2
Control (The group without Canagliflozin)
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 65 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Subjects are the patients who need oral hypoglycemic agents (OHA) even after diet and exercise therapy, and who need additional OHA in other OHA users than SGLT2 inhibitor.
Inclusion criteria
1) Informed consent (IC) from the patient him/herself.
2) >=65 year-old (Female/Male)
3) HbA1c >=6.5%, and HbA1c <10.0% within 8 weeks. HbA1c >=7.0% in case of administration of sulfonylurea, and/or glinide
4) History of heart failure before consent, and echocardiographic mean E/e' >14 (septal E/e' >15, or lateral E/e' >13 ) , or septal e' <7 cm/min, or lateral e' <10 sec/min and LV ejection fraction >=50%, with or without atrial fibrillation (AF)
5) Plasma BNP >=100 pg/mL or plasma NT-proBNP >=400 pg/mL before consent, or plasma BNP >=40 pg/mL or plasma NT-proBNP >=125 pg/mL within 8 weeks before consent, with or without atrial fibrillation (AF)
6) NYHA II or III (<8 weeks from IC)
7) No history of change in drug regimens (<8 weeks from IC)
Key exclusion criteria
Exclusion criteria
1) Type 1 DM
2) Treated with GLP-1
3) Patients who need insulin (severe ketosis, diabetic coma or pre-coma, severe infection, peri-operative, severe trauma)
4) Severe renal dysfunction or chronic renal failure during dialysis (In case of moderate renal dysfunction, patients are carefully judged the need for administration of canagliflozin)
5) ACS, CVD, myocarditis, contractile pericarditis, severe HVD (<12 weeks from IC)
6) NYHA IV
7) BMI<18.5kg/ m2
8) The pregnant, breastfeeder
9) Diagnosed or suspected malignant tumors (Patients who did not treat anti-cancer treatment within 1 year before consent can be entered.)
10) Inappropriate patients inappropriate to be included for some reasons
Target sample size
80
Research contact person
Name of lead principal investigator
| 1st name | Yoshihiko |
| Middle name | |
| Last name | Saito |
Organization
Nara Medical University
Division name
Department of cardiovascular Medicine
Zip code
634-8522
Address
840 Shijo, Kashihara, Nara 634-8522, Japan
TEL
0744-22-3051
yssaito@naramed-u.ac.jp
Public contact
Name of contact person
| 1st name | Masato |
| Middle name | |
| Last name | Kasahara |
Organization
Nara Medical University Hospital
Division name
Institute for Clinical and Translational Science
Zip code
634-8522
Address
840 Shijo, Kashihara, Nara 634-8522, Japan
TEL
0744-22-3051
Homepage URL
kasa@naramed-u.ac.jp
Sponsor or person
Institute
Nara Medical Univercity
Institute
Department
Personal name
Funding Source
Organization
Mitsubishi Tanabe Pharma Corporation
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Nara Medical University Certified Review Board
Address
840 Shijo, Kashihara, Nara 634-8522, Japan
Tel
0744-22-3051
ethics_nara@naramed-u.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
日本医科大学武蔵小杉病院（神奈川県）
公立陶生病院（愛知県）
信州大学医学部（長野県）
熊本大学大学院（熊本県）
国立循環器病研究センター（大阪府）
鳥取大学医学部（鳥取県）
兵庫医科大学（兵庫県）
福島県立医科大学（福島県）
平光ハートクリニック（愛知県）
大西ハートクリニック（三重県）
大阪大学大学院（大阪府）
洛和会丸太町病院（京都府）
奈良県西和医療センター（奈良県）
市立奈良病院（奈良県）
南奈良総合医療センター（奈良県）
草津総合病院（滋賀県）
日本心臓血圧研究振興会附属榊原記念病院（東京都）
坂口クリニック（奈良県）
クリニック神宮前（奈良県）
中谷医院（奈良県）
ふじい内科医院（奈良県）
酢谷内科（奈良県）
すぎもと内科クリニック（奈良県）
桐山医院（奈良県）
北海道大学大学院医学研究院（北海道）
群馬大学医学部付属病院（群馬県）
社会福祉法人大阪暁明館 大阪暁明館病院（大阪府）
医療法人新生会 総合病院 高の原中央病院（奈良県）
中山内科・循環器内科クリニック（熊本県）
Other administrative information
Date of disclosure of the study information
| 2017 | Year | 10 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2017 | Year | 08 | Month | 05 | Day |
Date of IRB
| 2017 | Year | 09 | Month | 25 | Day |
Anticipated trial start date
| 2017 | Year | 10 | Month | 01 | Day |
Last follow-up date
| 2020 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
| 2021 | Year | 03 | Month | 31 | Day |
Other
Other related information
Management information
Registered date
| 2017 | Year | 08 | Month | 15 | Day |
Last modified on
| 2021 | Year | 08 | Month | 19 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032801
